



2007-06-07

Pressrelease

### **"Jackpot in sight for Oasmia"**

**This is what the analysis company Redeye says in a recently presented analysis of the company.**

Oasmia Pharmaceutical has developed a new way of improving the widely used pharmaceutical Taxol®. Oasmia Pharmaceutical's product Paclical® is developed for use in human and in dogs.

The full version of the analysis can be found at [www.redeye.se](http://www.redeye.se) or [www.oasmia.com](http://www.oasmia.com).

---

More information is available at [www.ngm.se](http://www.ngm.se) or [www.oasmia.com](http://www.oasmia.com). For further information contact [info@oasmia.com](mailto:info@oasmia.com) or call +46 18 50 54 40.

*Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. Oasmia develops pharmaceuticals for the future.*

*A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is noted on NGM Nordic MTF.*